Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1364-8535
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated) ; volume:14 ; number:6 ; day:21 ; month:12 ; year:2010 ; pages:1-14 ; date:12.2010
Critical care ; 14, Heft 6 (21.12.2010), 1-14, 12.2010
- Beteiligte Personen und Organisationen
-
Shorr, Andrew F.
Janes, Jonathan M.
Artigas, Antonio
Tenhunen, Jyrki
Wyncoll, Duncan LA
Mercier, Emmanuelle
François, Bruno
Vincent, Jean-Louis
Vangerow, Burkhard
Heiselman, Darell
Leishman, Amy G.
Zhu, Yajun E.
Reinhart, Konrad
SpringerLink (Online service)
- DOI
-
10.1186/cc9382
- URN
-
urn:nbn:de:1111-20160809339
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shorr, Andrew F.
- Janes, Jonathan M.
- Artigas, Antonio
- Tenhunen, Jyrki
- Wyncoll, Duncan LA
- Mercier, Emmanuelle
- François, Bruno
- Vincent, Jean-Louis
- Vangerow, Burkhard
- Heiselman, Darell
- Leishman, Amy G.
- Zhu, Yajun E.
- Reinhart, Konrad
- SpringerLink (Online service)
Ähnliche Objekte (12)
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Can activated long-term memory maintain serial order information?
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Drotrecogin alfa (activated): real-life use and outcomes for the UK
Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Can activated long-term memory maintain serial order information?
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Drotrecogin alfa (activated): real-life use and outcomes for the UK
Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)
Can activated long-term memory maintain serial order information?
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Drotrecogin alfa (activated): real-life use and outcomes for the UK